Ozempic in pill form shows promising results

Embargoed until: Publicly released: 2025-09-18 07:00

International

Photo by James Yarema on Unsplash

Novo Nordisk, the developer of the injectable diabetes and weight loss drug Ozempic, has released study results suggesting a pill form of the drug can be safe and effective. 205 participants took the oral semaglutide pill for 64 weeks alongside 102 participants taking a non-active placebo pill. The researchers say the semaglutide group lost an average of 13% of their body weight during the study compared to 2.2% for the placebo group. Gastrointestinal issues such as nausea or indigestion were more common for those taking semaglutide, the researchers say, but these problems were generally moderate to mild. The researchers say this pill could be an effective alternative for people who can't use an injectable drug for various reasons.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: University of Toronto, Canada, Wharton Weight Management Clinic, Canada

Funder: Supported by Novo Nordisk, Denmark.

Media Contact/s

Contact details are only visible to registered journalists.